| [1] |
Wang D, Zheng X, Fu B, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling[J]. EBioMedicine, 2019(46):119-132.
|
| [2] |
Chen H, Lu D, Yang X, et al. One shoot, two birds: alleviating inflammation caused by ischemia/reperfusion injury to reduce the recurrence of hepatocellular carcinoma[J]. Front Immunol, 2022(13):879552.
|
| [3] |
Cannito S, Turato C, Paternostro C, et al. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells[J]. Oncotarget, 2015, 6(4):2206-2221.
|
| [4] |
Mu H, Yu G, Li H, et al. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation[J]. Cell Oncol, 2021, 44(5):1151-1166.
|
| [5] |
Turato C, Vairetti M, Cagna M, et al. SerpinB3 administration protects liver against ischemia-reperfusion injury[J]. Eur J Histochem, 2022, 66(4):3561.
|
| [6] |
Kung-Chun Chiu D, Pui-Wah Tse A, Law C T, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway[J]. Cell Death Dis, 2019, 10(12):934.
|
| [7] |
Chang H, Li J, Qu K, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NF-κB pathway in hepatocellular carcinoma[J]. Cell Death Dis, 2020, 11(5):332.
|
| [8] |
Luis G, Godfroid A, Nishiumi S, et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence[J]. Redox Biol, 2021(43):102006.
|
| [9] |
Matsumoto K, Satoh Y, Sugo H, et al. Immunohistochemical study of the relationship between 8-hydroxy-2'-deoxyguanosine levels in noncancerous region and postoperative recurrence of hepatocellular carcinoma in remnant liver[J]. Hepatol Res, 2003, 25(4):435-441.
|
| [10] |
Yugawa K, Itoh S, Yoshizumi T, et al. Prognostic impact of 8-hydroxy-deoxyguanosine and its repair enzyme 8-hydroxy-deoxyguanosine DNA glycosylase in hepatocellular carcinoma[J]. Pathol Int, 2020, 70(8):533-541.
|
| [11] |
Pang L, Yeung OWH, Ng KTP, et al. Postoperative plasmacytoid dendritic cells secrete IFNα to promote recruitment of myeloid-derived suppressor cells and drive hepatocellular carcinoma recurrence[J]. Cancer Res, 2022, 82(22):4206-4218.
|
| [12] |
陶璇, 王斌, 陈虹, 等. 肝细胞癌中精氨酸酶1和诱导型一氧化氮合成酶表达的临床意义及其相关性研究[J]. 中华肝脏病杂志, 2020, 28(11):924-929.
|
| [13] |
Sun MH, Han XC, Jia MK, et al. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma[J]. World J Gastroenterol, 2005, 11(38):5931-5937.
|
| [14] |
Yu H, Lin L, Zhang Z, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study[J]. Signal Transduct Target Ther, 2020, 5(1):209.
|
| [15] |
Yokoo H, Yasuda J, Nakanishi K, et al. Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma[J]. Hepatol Res, 2011, 41(3):240-249.
|
| [16] |
Pocino K, Stefanile A, Basile V, et al. Cytokines and hepatocellular carcinoma: biomarkers of a deadly embrace[J]. J Pers Med, 2022, 13(1):5.
|
| [17] |
Iwahasi S, Rui F, Morine Y, et al. Hepatic stellate cells contribute to the tumor malignancy of hepatocellular carcinoma through the IL-6 pathway[J]. Anticancer Res, 2020, 40(2):743-749.
|
| [18] |
皮丽娜, 候艳莹, 张维. 肠道菌群失调、炎症因子变化、维生素缺乏与肝癌患者根治术后复发的关系[J]. 现代肿瘤医学, 2019, 27(17):3078-3081.
|
| [19] |
Zhang M, Zhang S, Yang Z, et al. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence[J]. Oncol Lett, 2018, 16(6):7158-7165.
|
| [20] |
Yang Z, Zhuang L, Szatmary P, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma[J]. Int J Med Sci, 2015, 12(3):256-263.
|
| [21] |
刘金钢, 李岩, 刘丹, 等. HSP70与PI3K/Akt信号通路在肝细胞肝癌组织中的表达及意义[J/OL]. 中华肝脏外科手术学电子杂志, 2013, 2(1):45-52.
|
| [22] |
Yang S, Xiao H, Cao L. Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment[J]. Biomed Pharmacother, 2021(142):112074.
|
| [23] |
Cho W, Jin X, Pang J, et al. The molecular chaperone heat shock protein 70 controls liver cancer initiation and progression by regulating adaptive DNA damage and mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathways[J]. Mol Cell Biol, 2019, 39(9):e00391-18.
|
| [24] |
Wang Q, Wang K, Tan X, et al. Immunomodulatory role of metalloproteases in cancers: current progress and future trends[J]. Front Immunol, 2022(13): 1064033.
|
| [25] |
Hwang KE, Kim HJ, Song IS, et al. Salinomycin suppresses TGF-β1-induced EMT by down-regulating MMP-2 and MMP-9 via the AMPK/SIRT1 pathway in non-small cell lung cancer[J]. Int J Med Sci, 2021, 18(3):715-726.
|
| [26] |
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3):212-226.
|
| [27] |
Cabral-Pacheco GA, Garza-Veloz I, Castruita-De La Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J]. Int J Mol Sci, 2020, 21(24):9739.
|
| [28] |
Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: deciphering the role of gut microbiome[J]. Adv Cancer Res, 2021(149):171-255.
|
| [29] |
付豪爽, 赵爽, 谢青. 肠道菌群促进肝癌发生的机制及其临床应用[J]. 肝脏, 2021, 26(6):696-700.
|
| [30] |
Bartolini I, Risaliti M, Tucci R, et al. Gut microbiota and immune system in liver cancer: promising therapeutic implication from development to treatment[J]. World J Gastrointest Oncol, 2021, 13(11):1616-1631.
|
| [31] |
Zhang C, Yang M, Ericsson AC. The potential gut microbiota-mediated treatment options for liver cancer[J]. Front Oncol, 2020(10):524205.
|
| [32] |
Shen S, Khatiwada S, Behary J, et al. Modulation of the gut microbiome to improve clinical outcomes in hepatocellular carcinoma[J]. Cancers, 2022, 14(9):2099.
|
| [33] |
Spanu D, Pretta A, Lai E, et al. Hepatocellular carcinoma and microbiota: implications for clinical management and treatment[J]. World J Hepatol, 2022, 14(7):1319-1332.
|
| [34] |
Torti SV, Manz DH, Paul BT, et al. Iron and cancer[J]. Annu Rev Nutr, 2018(38):97-125.
|
| [35] |
Toyokuni S, Ito F, Yamashita K, et al. Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis[J]. Free Radic Biol Med, 2017(108):610-626.
|
| [36] |
Kim SE, Zhang L, Ma K, et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth[J]. Nat Nanotechnol, 2016, 11(11):977-985.
|
| [37] |
Wu J, Wang Y, Jiang R, et al. Ferroptosis in liver disease: new insights into disease mechanisms[J]. Cell Death Discov, 2021, 7(1):276.
|